Waheed Jamal, Boehringer Ingelheim’s head of cardio, renal and metabolic medicine
Boehringer Ingelheim unveils mid-stage win for glucagon/GLP-1 candidate for MASH, kindling PhIII plans
Boehringer Ingelheim said on Monday that its “double G” metabolic dysfunction-associated steatohepatitis (MASH) drug delivered positive topline results in a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
